Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TransCon TLR7/8 Agonist |
Synonyms | |
Therapy Description |
TransCon TLR7/8 Agonist is a hydrogel based formulation of an imidazoquinolinamine and resiquimod, which acts as an agonist of TLR 7 and TLR8, which potentially activates the antitumor immune response and may lead to tumor cell lysis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TransCon TLR7/8 Agonist | Resiquimod Hydrogel-based Sustained-release formulation | TLR7 Agonist 12 TLR8 Agonist 9 | TransCon TLR7/8 Agonist is a hydrogel based formulation of an imidazoquinolinamine and resiquimod, which acts as an agonist of TLR 7 and TLR8, which potentially activates the antitumor immune response and may lead to tumor cell lysis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04799054 | Phase Ib/II | Pembrolizumab + TransCon TLR7/8 Agonist TransCon TLR7/8 Agonist | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | NLD | ESP | AUS | 2 |